Academic Journal
View in EDS
Linked Full Text

Pharmacist involvement in antifungal stewardship programs: a systematic review of clinical, utilization, and economic outcomes.

Bibliographic Details
Title: Pharmacist involvement in antifungal stewardship programs: a systematic review of clinical, utilization, and economic outcomes.
Authors: Kara E; Department of Clinical Pharmacy, Hacettepe University Faculty of Pharmacy, Altindag, Ankara, Turkey. emrekara@hacettepe.edu.tr., Sahin N; Hacettepe University Faculty of Pharmacy, Ankara, Turkey., Yumrucu FG; Department of Clinical Pharmacy, Hacettepe University Faculty of Pharmacy, Altindag, Ankara, Turkey., Metan G; Department of Infectious Diseases and Clinical Microbiology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Source: International journal of clinical pharmacy [Int J Clin Pharm] 2026 Aug; Vol. 48 (4), pp. 1214-1227. Date of Electronic Publication: 2026 Apr 24.
Publication Type: Journal Article; Systematic Review; Review
Language: English
Journal Info: Publisher: Springer Country of Publication: Netherlands NLM ID: 101554912 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2210-7711 (Electronic) NLM ISO Abbreviation: Int J Clin Pharm Subsets: MEDLINE
Imprint Name(s): Original Publication: Dordrecht : Springer
MeSH Terms: Antifungal Agents*/economics , Antifungal Agents*/therapeutic use , Antifungal Agents*/administration & dosage , Pharmacists*/organization & administration , Pharmacists*/economics , Antimicrobial Stewardship*/economics , Professional Role*, Humans
Abstract: Introduction: Antifungal stewardship programs are increasingly implemented to optimize antifungal use. Pharmacists are frequently involved in these programs; however, their specific contributions and impact have not been systematically characterized.
Aim: The aim of this systematic review was to synthesize the available evidence regarding the role and impact of pharmacists in antifungal stewardship programs, specifically focusing on clinical, utilization, and economic outcomes, using a narrative synthesis approach.
Method: A systematic review was conducted. PubMed/MEDLINE and Scopus databases were searched for studies published from database inception to January 2026. Two reviewers independently screened titles, abstracts, and full texts according to predefined eligibility criteria. Data extraction was performed independently using a standardized form. Due to heterogeneity in study designs and outcomes, a narrative synthesis approach was applied. The review was reported in accordance with the PRISMA reporting guidelines. Risk of bias was assessed using the ROBINS-I tool for non-randomized studies.
Results: Fifteen studies met the inclusion criteria, the majority of which were quasi-experimental pre-post intervention studies conducted in tertiary care hospitals. Key pharmacist-driven interventions included antifungal dose optimization, de-escalation or discontinuation of therapy, facilitation of early appropriate antifungal treatment, therapeutic drug monitoring, and education or protocol development. Across studies, pharmacist involvement was associated with improvements in antifungal prescribing quality and stewardship process outcomes, including potential improvements in duration of antifungal therapy, antifungal consumption (measured by defined-daily-doses or days-of-therapy), time to appropriate therapy, and antifungal-related costs. Effects on clinical outcomes such as mortality and length of hospital stay were variable and generally not statistically significant. The overall certainty of the evidence is low to very low by the observational nature and the moderate-to-serious risk of bias of the included studies.
Conclusion: Pharmacist participation in multidisciplinary antifungal stewardship teams may be associated with improved antifungal utilization and adherence to guidelines in hospitalized adults. The findings support that pharmacists are important members of multidisciplinary teams in antifungal stewardship.
(© 2026. The Author(s).)
Competing Interests: Declarations. Competing interests: The authors declare no competing interests. Ethics approval: Not relevant.
References: Roemer T, Krysan DJ. Antifungal drug development: challenges, unmet clinical needs, and new approaches. Cold Spring Harb Perspect Med. 2014;4:a019703. https://doi.org/10.1101/cshperspect.a019703 . (PMID: 10.1101/cshperspect.a019703247898783996373)
Maskarinec SA, Johnson MD, Perfect JR. Genetic susceptibility to fungal infections: What is in the genes? Curr Clin Microbiol Rep. 2016;3(2):81–91. https://doi.org/10.1007/s40588-016-0037-3 . (PMID: 10.1007/s40588-016-0037-3275477004988683)
Richardson MD. Changing patterns and trends in systemic fungal infections. J Antimicrob Chemother. 2005;56(Suppl 1):i5–11. https://doi.org/10.1093/jac/dki218 . (PMID: 10.1093/jac/dki21816120635)
Bassetti M, Garnacho-Montero J, Calandra T, et al. Intensive care medicine research agenda on invasive fungal infection in critically ill patients. Intensive Care Med. 2017;43(9):1225–38. https://doi.org/10.1007/s00134-017-4731-2 . (PMID: 10.1007/s00134-017-4731-228255613)
Perlin DS, Rautemaa-Richardson R, Alastruey-Izquierdo A. The global problem of antifungal resistance: prevalence, mechanisms, and management. Lancet Infect Dis. 2017;17(12):e383–92. https://doi.org/10.1016/s1473-3099(17)30316-x . (PMID: 10.1016/s1473-3099(17)30316-x28774698)
Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an antibiotic stewardship program: guidelines by the infectious diseases society of America and the society for healthcare epidemiology of America. Clin Infect Dis. 2016;62(10):e51-77. https://doi.org/10.1093/cid/ciw118 . (PMID: 10.1093/cid/ciw118270809925006285)
Johnson MD, Lewis RE, Dodds Ashley ES, et al. Core recommendations for antifungal stewardship: a statement of the mycoses study group education and research consortium. J Infect Dis. 2020;222(Suppl 3):S175–98. https://doi.org/10.1093/infdis/jiaa394 . (PMID: 10.1093/infdis/jiaa394327568797403757)
Gupta AK, Versteeg SG, Shear NH. Common drug-drug interactions in antifungal treatments for superficial fungal infections. Expert Opin Drug Metab Toxicol. 2018;14(4):387–98. https://doi.org/10.1080/17425255.2018.1461834 . (PMID: 10.1080/17425255.2018.146183429633864)
Zimmermann T, Yeates RA, Laufen H, et al. Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur J Clin Pharmacol. 1994;46(2):147–50. https://doi.org/10.1007/BF00199879 . (PMID: 10.1007/BF001998798039534)
Ullmann AJ, Akova M, Herbrecht R, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect. 2012;18(Suppl 7):53–67. https://doi.org/10.1111/1469-0691.12041 . (PMID: 10.1111/1469-0691.1204123137137)
Arnold HM, Micek ST, Shorr AF, et al. Hospital resource utilization and costs of inappropriate treatment of candidemia. Pharmacotherapy. 2010;30(4):361–8. https://doi.org/10.1592/phco.30.4.361 . (PMID: 10.1592/phco.30.4.36120334456)
Khanina A, Tio SY, Ananda-Rajah MR, et al. Consensus guidelines for antifungal stewardship, surveillance and infection prevention, 2021. Intern Med J. 2021;51(Suppl 7(Suppl 1)):18–36. https://doi.org/10.1111/imj.15586 . (PMID: 10.1111/imj.15586349371348206820)
McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): an R package and shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021;12(1):55–61. https://doi.org/10.1002/jrsm.1411 . (PMID: 10.1002/jrsm.141132336025)
Koh L, Shah PJ, Korulla A, et al. Incorporation of rapid diagnostic tests to improve time to antimicrobial therapy for gram-positive bacteremia and candidemia. Am J Health Syst Pharm. 2020;77(8):622–31. https://doi.org/10.1093/ajhp/zxaa030 . (PMID: 10.1093/ajhp/zxaa03032123897)
Reed EE, West JE, Keating EA, et al. Improving the management of candidemia through antimicrobial stewardship interventions. Diagn Microbiol Infect Dis. 2014;78(2):157–61. https://doi.org/10.1016/j.diagmicrobio.2013.11.012 . (PMID: 10.1016/j.diagmicrobio.2013.11.01224316015)
Pettit NN, Han Z, Nguyen CT, et al. Antimicrobial stewardship review of automated candidemia alerts using the epic stewardship module improves bundle-of-care adherence. Open Forum Infect Dis. 2019;6:ofz412. https://doi.org/10.1093/ofid/ofz412 . (PMID: 10.1093/ofid/ofz412316603706788339)
Moni M, Sidharthan N, Sudhir S, et al. A quality improvement initiative to improve the appropriateness of candidemia management by the implementation of a comprehensive candidemia care bundle at a tertiary care hospital in South India: results of a quasi-experimental study. Medicine Baltimore. 2022;101(13):e28906. https://doi.org/10.1097/md.0000000000028906 . (PMID: 10.1097/md.0000000000028906354210579276434)
Kara E, Metan G, Bayraktar-Ekincioglu A, et al. Implementation of pharmacist-driven antifungal stewardship program in a tertiary care hospital. Antimicrob Agents Chemother. 2021;65(9):10–128. https://doi.org/10.1128/aac.00629-21 . (PMID: 10.1128/aac.00629-21)
Samura M, Hirose N, Kurata T, et al. Support for fungal infection treatment mediated by pharmacist-led antifungal stewardship activities. J Infect Chemother. 2020;26(3):272–9. https://doi.org/10.1016/j.jiac.2019.09.016 . (PMID: 10.1016/j.jiac.2019.09.01631732440)
Lachenmayr SJ, Strobach D, Berking S, et al. Improving quality of antifungal use through antifungal stewardship interventions. Infection. 2019;47(4):603–10. https://doi.org/10.1007/s15010-019-01288-4 . (PMID: 10.1007/s15010-019-01288-430805898)
Al-Somai N, Al-Muhur M, Quteimat O, et al. The impact of clinical pharmacist and ID intervention in rationalization of antimicrobial use. Saudi Pharm J. 2014;22(6):516–21. https://doi.org/10.1016/j.jsps.2014.02.003 . (PMID: 10.1016/j.jsps.2014.02.003255618634281637)
Keck JM, Cretella DA, Stover KR, et al. Evaluation of an antifungal stewardship initiative targeting micafungin at an academic medical center. Antibiotics. 2023. https://doi.org/10.3390/antibiotics12020193 . (PMID: 10.3390/antibiotics12020193368301049952013)
Whitney L, Al-Ghusein H, Glass S, et al. Effectiveness of an antifungal stewardship programme at a London teaching hospital 2010–16. J Antimicrob Chemother. 2018;74(1):234–41. https://doi.org/10.1093/jac/dky389 . (PMID: 10.1093/jac/dky389)
Markogiannakis A, Korantanis K, Gamaletsou MN, et al. Impact of a non-compulsory antifungal stewardship program on overuse and misuse of antifungal agents in a tertiary care hospital. Int J Antimicrob Agents. 2021;57(1):106255. https://doi.org/10.1016/j.ijantimicag.2020.106255 . (PMID: 10.1016/j.ijantimicag.2020.10625533279582)
Ioannidis K, Papachristos A, Skarlatinis I, et al. Do we need to adopt antifungal stewardship programmes? Eur J Hosp Pharm. 2020;27(1):14–8. https://doi.org/10.1136/ejhpharm-2017-001467 . (PMID: 10.1136/ejhpharm-2017-00146732064083)
Standiford HC, Chan S, Tripoli M, et al. Antimicrobial stewardship at a large tertiary care academic medical center: cost analysis before, during, and after a 7-year program. Infect Control Hosp Epidemiol. 2012;33(4):338–45. https://doi.org/10.1086/664909 . (PMID: 10.1086/66490922418628)
Morris AM, Bai A, Burry L, et al. Long-term effects of phased implementation of antimicrobial stewardship in academic ICUs: 2007–2015*. Crit Care Med. 2019;47(2):159–66. https://doi.org/10.1097/ccm.0000000000003514 . (PMID: 10.1097/ccm.000000000000351430407951)
Cappelletty D, Jacobs D. Evaluating the impact of a pharmacist’s absence from an antimicrobial stewardship team. Am J Health Syst Pharm. 2013;70(12):1065–9. https://doi.org/10.2146/ajhp120482 . (PMID: 10.2146/ajhp12048223719885)
Webb BJ, Ferraro JP, Rea S, et al. Epidemiology and clinical features of invasive fungal infection in a US health care network. Open Forum Infect Dis. 2018;5:ofy187. https://doi.org/10.1093/ofid/ofy187 . (PMID: 10.1093/ofid/ofy187301514126104777)
Hart E, Nguyen M, Allen M, et al. A systematic review of the impact of antifungal stewardship interventions in the United States. Ann Clin Microbiol Antimicrob. 2019;18(1):24. https://doi.org/10.1186/s12941-019-0323-z . (PMID: 10.1186/s12941-019-0323-z314345636702721)
Chen SC, Sorrell TC, Chang CC, et al. Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014. Intern Med J. 2014;44(12b):1315–32. https://doi.org/10.1111/imj.12597 . (PMID: 10.1111/imj.1259725482743)
Furlan G, Caduff-Janosa P, Sottosanti L, et al. Drug safety in geriatric patients: current status and proposed way forward. Drug Saf. 2020;43(9):853–66. https://doi.org/10.1007/s40264-020-00949-w . (PMID: 10.1007/s40264-020-00949-w32500271)
Mantadakis E, Pana ZD, Zaoutis T. Candidemia in children: epidemiology, prevention and management. Mycoses. 2018;61(9):614–22. https://doi.org/10.1111/myc.12792 . (PMID: 10.1111/myc.1279229762868)
Contributed Indexing: Keywords: Antifungal agents; Antifungal stewardship; Antimicrobial stewardship; Inpatients; Mycoses; Pharmacists
Substance Nomenclature: 0 (Antifungal Agents)
Entry Date(s): Date Created: 20260424 Date Completed: 20260714 Latest Revision: 20260726
Update Code: 20260726
PubMed Central ID: PMC13369351
DOI: 10.1007/s11096-026-02149-5
PMID: 42029838
Database: MEDLINE
Description
ISSN:2210-7711
DOI:10.1007/s11096-026-02149-5